GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Klaria Pharma Holding AB (OSTO:KLAR) » Definitions » Debt-to-Equity

Klaria Pharma Holding AB (OSTO:KLAR) Debt-to-Equity : 0.00 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Klaria Pharma Holding AB Debt-to-Equity?

Klaria Pharma Holding AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Klaria Pharma Holding AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Klaria Pharma Holding AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr29.22 Mil. Klaria Pharma Holding AB's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Klaria Pharma Holding AB's Debt-to-Equity or its related term are showing as below:

OSTO:KLAR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09   Med: 0.23   Max: 0.46
Current: 0.65

During the past 10 years, the highest Debt-to-Equity Ratio of Klaria Pharma Holding AB was 0.46. The lowest was 0.09. And the median was 0.23.

OSTO:KLAR's Debt-to-Equity is ranked worse than
73.96% of 845 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs OSTO:KLAR: 0.65

Klaria Pharma Holding AB Debt-to-Equity Historical Data

The historical data trend for Klaria Pharma Holding AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klaria Pharma Holding AB Debt-to-Equity Chart

Klaria Pharma Holding AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.09 0.46 0.23 0.46

Klaria Pharma Holding AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.46 -

Competitive Comparison of Klaria Pharma Holding AB's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Klaria Pharma Holding AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Klaria Pharma Holding AB's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Klaria Pharma Holding AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Klaria Pharma Holding AB's Debt-to-Equity falls into.



Klaria Pharma Holding AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Klaria Pharma Holding AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Klaria Pharma Holding AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Klaria Pharma Holding AB  (OSTO:KLAR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Klaria Pharma Holding AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Klaria Pharma Holding AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Klaria Pharma Holding AB (OSTO:KLAR) Business Description

Traded in Other Exchanges
Address
Virdings Alle 2, Uppsala, SWE, 754 50
Klaria Pharma Holding AB is engaged in the development and commercialization of pharmaceutical products in Sweden for migraine and cancer-related pain. Its operations are based on a patented drug delivery platform in the form of an alginate-based polymer film. Majority of the group's operations are conducted in Sweden.

Klaria Pharma Holding AB (OSTO:KLAR) Headlines

No Headlines